

Financial Supervision Authority

Current report no. 61/2018

Date prepared: 2018-12-05

Abbreviated name of the issuer: MABION S.A.

**Subject:**

Filing an application for an extension of patent protection in PCT procedure as part of the MabionMS project

Legal basis Article 17 para. 1 MAR - confidential information.

**Contents of the report:**

In reference to the Current Report No. 56/2017 of December 5, 2017 regarding the submission of the European patent application for the invention entitled "Combination Therapy of Multiple Sclerosis comprising a CD20 Ligand", the Board of Mabion S.A. ("Issuer") informs that today the patent agent of the Company submitted to the European Patent Office in Hague a notification regarding the extension of this patent protection in PCT procedure.

The subject of the patent application is an innovative therapy for the treatment of patients suffering from multiple sclerosis with the use of MabionCD20 antibody combined with other substances (MabionMS project).

Filing an application does not mean a guarantee of obtaining the patent protection.